TY - JOUR
T1 - COVID-19 Vaccination and Uveitis
T2 - Epidemiology, Clinical Features and Visual Prognosis
AU - Ferrand, Nawfel
AU - Accorinti, Massimo
AU - Agarwal, Mamta
AU - Spartalis, Christoph
AU - Manni, Priscilla
AU - Stuebiger, Nicole
AU - Zierhut, Manfred
N1 - Publisher Copyright:
© 2022 Taylor & Francis Group, LLC.
PY - 2022
Y1 - 2022
N2 - Purpose: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination. Patients and Methods: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services. Results: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p <.01). Conclusion: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.
AB - Purpose: To study the epidemiological and clinical features of uveitis post-COVID-19 vaccination. Patients and Methods: Retrospective chart review of patients presenting with uveitis after COVID-19 vaccination in tertiary uveitis services. Results: In total, 25 patients, 76% females, mean age 43.2 years, were included. Uveitis occurred after Pfizer, Moderna, Astra-Zeneca and Covaxin vaccination. Anterior uveitis was the most frequent type of uveitis (56%). History of uveitis was found in 19 cases (76%), among whom 90.9% of the tested patients developed anti-Sars-CoV-2 spike antibodies after vaccination. In a mean follow-up of 5 months, one-line decrease in visual acuity was found in 12% of patients. During post-vaccine uveitis, 15.8% of cases needed an increase in their systemic therapy. According to Naranjo score, new-onset uveitis had a higher probability of being associated with vaccination (p <.01). Conclusion: COVID-19 vaccination can cause uveitis but has no significant impact on the visual prognosis after resolution.
KW - Adverse events
KW - COVID-19 vaccination
KW - side effects
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85129220869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85129220869&partnerID=8YFLogxK
U2 - 10.1080/09273948.2022.2058964
DO - 10.1080/09273948.2022.2058964
M3 - Letter
C2 - 35404757
AN - SCOPUS:85129220869
SN - 0927-3948
VL - 30
SP - 1265
EP - 1273
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - 5
ER -